ENDRA Life Sciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ENDRA Life Sciences Inc. (NDRA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-11.5110.06-13.18-11.23-11.73-13.31-9.80
Depreciation & Amortization0.210.280.230.220.172.470.07
Stock Based Compensation0.571.001.201.442.100.000.00
Change in Working Capital0.13-0.77-1.03-1.16-1.520.63-0.36
Change in Inventory0.24-0.12-1.36-0.69-0.480.000.00
Change in Accounts Payable-0.20-0.820.110.49-0.830.000.00
Change in Other Working Capital0.100.020.22-1.06-0.210.000.00
Other Operating Activities3.190.961.071.352.041.622.10
Net Cash from Operating Activities-7.40-9.55-12.77-11.12-10.75-8.59-7.70
Investing Activities
Capital Expenditures-0.020.03-0.200.05-0.080.04-0.10
Other Investing Activities0.000.000.000.000.000.000.00
Net Cash from Investing Activities-0.01-0.02-0.20-0.05-0.08-0.04-0.10
Financing Activities
Debt Repayment-0.030.000.000.000.000.000.00
Common Stock Issued1.156.488.4010.6211.540.137.74
Dividends Paid-0.010.000.000.000.000.000.00
Other Financing Activities6.691.030.000.001.05-0.300.00
Net Cash from Financing Activities7.817.528.4013.4011.888.048.67
Summary
Effect of Forex Changes on Cash0.000.000.007.230.000.000.00
Net Change in Cash0.40-2.06-4.572.231.05-0.590.87
Cash at Beginning of Period2.834.899.467.236.176.475.60
Cash at End of Period3.234.894.899.467.235.886.47
Free Cash Flow-7.42-9.57-12.97-11.17-10.82-8.63-7.80
Supplemental Disclosures
Interest Paid0.030.040.060.060.000.000.04